Covid-19 Antibody Treatments Need More Work: Johns Hopkins

The video discusses the role of antibodies and T cells in COVID-19 immunity, comparing natural infection and vaccine-induced antibodies. It highlights the ongoing research to understand the immune response and the importance of phase three trials in determining vaccine efficacy and safety. The video also addresses the rapid development of promising vaccine candidates and the challenges in ensuring broad protection and large-scale production.

What is the main challenge in determining the effectiveness of antibodies produced by vaccines?

• Antibodies are not produced in phase one trials.

• Antibodies do not last long enough.

• It is unclear if antibodies confer protection.

• Vaccines do not produce antibodies.

How might T cells contribute to immunity against COVID-19?

• By causing adverse reactions.

• By replacing the need for vaccines.

• By providing immunity even without antibodies.

• By producing antibodies directly.

What is a significant focus of current research regarding T cells and COVID-19?

• Understanding their role in immunity.

• Developing T cell-based vaccines.

• Eliminating the need for antibodies.

• Reducing vaccine production time.

What is a critical aspect of phase three vaccine trials?

• Ensuring broad protection for the population.

• Determining the number of doses required.

• Testing vaccines on animals.

• Identifying the fastest production method.

What is the current status of vaccine candidates as they enter phase three trials?

• They have shown no adverse events.

• They are ready for global distribution.

• They are promising but still under evaluation.

• They have failed to produce antibodies.